从中心到边缘:PET空间代谢异质性指标NHOC与NHOP的预后价值系统综述与荟萃分析
结果显示,NHOC升高与总生存期(OS)较差显著相关(HR 2.313,95%CI 1.418–3.775,p=0.001),肺癌亚组关联更强(HR 2.864,95%CI 2.018–4.063,p<0.001)。NHOP降低与无进展生存期(PFS)较差呈非显著趋势(HR 2.92,95%CI 0.71–11.92)。
要点
- NHOC升高与OS较差显著相关,合并HR 2.313(95%CI 1.418–3.775,p=0.001)。
- 肺癌亚组NHOC与OS关联更强(HR 2.864,95%CI 2.018–4.063,p<0.001)。
- NHOP降低与PFS较差呈非显著趋势(HR 2.92,95%CI 0.71–11.92)。
核心结论
- PET衍生的空间生物标志物尤其是NHOC,有望作为肿瘤侵袭性和生存结局的预后指标。
研究设计与样本
- 按照PRISMA指南开展系统综述与荟萃分析,检索PubMed/MEDLINE和Google Scholar至2026年3月。
- 采用随机效应模型合并OS和PFS的风险比(HR)。
主要发现
- NHOC升高与OS较差显著相关,合并HR为2.313(95%CI 1.418–3.775,p=0.001)。
- 肺癌亚组中NHOC与OS的关联更强,HR为2.864(95%CI 2.018–4.063,p<0.001)。
- 乳腺癌和胶质瘤因数据有限,结果尚不确定。
- NHOP降低与PFS较差呈非显著趋势,HR为2.92(95%CI 0.71–11.92)。
- 基于NHOC的预测模型表现中等,AUC最高达0.77。
关键数值与推荐
- NHOC升高与OS较差的合并HR为2.313(95%CI 1.418–3.775,p=0.001)。
- 肺癌亚组NHOC与OS的HR为2.864(95%CI 2.018–4.063,p<0.001)。
- NHOP降低与PFS的HR为2.92(95%CI 0.71–11.92),无统计学显著性。
- 基于NHOC的预测模型AUC最高为0.77。
临床怎么用
- NHOC可作为PET影像中提示肿瘤侵袭性和生存预后的候选空间指标,尤其适用于肺癌。
- NHOP的预后价值尚不明确,暂不宜单独用于临床决策。
- 临床转化前需统一影像采集与分析协议,并开展多中心验证。
局限性
- 乳腺癌和胶质瘤数据有限,相关结论尚不确定。
- NHOP与PFS的关联未达统计学显著。
- 预测模型性能仅为中等(AUC最高0.77)。
- 需更大规模多中心研究及标准化影像协议验证临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tumor heterogeneity remains a major challenge in oncology, influencing prognosis and treatment response. Novel PET-derived spatial radiomic features, including the normalized hotspot-to-centroid (NHOC) and normalized hotspot-to-perimeter (NHOP) distances, aim to quantify intratumoral metabolic heterogeneity and spatial distribution of metabolic activity. These biomarkers may provide biologically interpretable indicators of tumor aggressiveness and patient outcomes. The aim of this study was to systematically evaluate the prognostic and predictive performance of NHOC and NHOP derived from PET imaging across different tumor types. METHODS: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed/MEDLINE and Google Scholar were searched up to March 2026. Studies evaluating NHOC or NHOP extracted from PET imaging in cancer patients were included. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were pooled using random-effects models. RESULTS: Ten studies involving 1,496 patients were included. Elevated NHOC was statistically significantly associated with worse OS (HR of 2.313, 95% CI [1.418, 3.775], p = 0.001). Subgroup analysis showed a strong association in lung cancers (2.864, 95% CI [2.018, 4.063], p < 0.001), while results in breast cancer and glioma were inconclusive due to limited data. Decrease in NHOP demonstrated a non-significant trend toward poorer PFS (HR = 2.92, 95% CI: 0.71-11.92). Predictive models based on NHOC showed moderate performance (AUC up to 0.77). CONCLUSIONS: PET-derived spatial biomarkers, particularly NHOC, show promise as prognostic indicators of tumor aggressiveness and survival outcomes. Larger multicenter studies with standardized imaging protocols are needed to validate their clinical utility.
引用
- Sadeghpour S, Sadeghi R, Aghaee A, et al. From center to edge: Prognostic implications of spatial metabolic heterogeneity, normalized hotspot-to-centroid and perimeter distance, on PET imaging. A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42429822. doi:10.1007/s00259-026-08038-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。